These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1650 related items for PubMed ID: 24859203

  • 1. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S.
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [Abstract] [Full Text] [Related]

  • 2. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
    Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K.
    Inflamm Bowel Dis; 2017 Jan; 23(1):97-106. PubMed ID: 27930408
    [Abstract] [Full Text] [Related]

  • 3. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
    Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG.
    Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
    [Abstract] [Full Text] [Related]

  • 4. Vedolizumab as induction and maintenance therapy for Crohn's disease.
    Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, GEMINI 2 Study Group.
    N Engl J Med; 2013 Aug 22; 369(8):711-21. PubMed ID: 23964933
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M.
    Clin Gastroenterol Hepatol; 2017 Feb 22; 15(2):229-239.e5. PubMed ID: 27639327
    [Abstract] [Full Text] [Related]

  • 6. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
    Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, van der Woude CJ, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D'Haens G.
    Gastroenterology; 2019 Oct 22; 157(4):997-1006.e6. PubMed ID: 31175865
    [Abstract] [Full Text] [Related]

  • 7. Vedolizumab in the treatment of Crohn's disease.
    Tarabar D, Hirsch A, Rubin DT.
    Expert Rev Gastroenterol Hepatol; 2016 Oct 22; 10(3):283-90. PubMed ID: 26810276
    [Abstract] [Full Text] [Related]

  • 8. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC, Bressler B.
    Immunotherapy; 2014 Oct 22; 6(9):963-71. PubMed ID: 25341118
    [Abstract] [Full Text] [Related]

  • 9. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 10. Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses.
    Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T.
    J Gastroenterol; 2020 Mar 19; 55(3):291-306. PubMed ID: 31836930
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
    Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, Colombel JF.
    Clin Gastroenterol Hepatol; 2019 Jan 19; 17(1):130-138.e7. PubMed ID: 29857145
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.
    Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T.
    Inflamm Bowel Dis; 2019 Jul 17; 25(8):1375-1382. PubMed ID: 30615117
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G.
    Gastroenterology; 2012 May 17; 142(5):1102-1111.e2. PubMed ID: 22326435
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 83.